Pfizer Strikes Multibillion-Dollar Deal to Take on Autoimmune Diseases
Pfizer Inc. (NYSE:PFE) announced Wednesday an exclusive licensing agreement with Starna Therapeutics worth up to $2.63 billion in upfront and milestone payments, plus royalties . The agreement expands Pfizer’s inflammation and immunology pipeline while strengthening its presence in next-generation cell therapies. Deal Terms and Financial Details Starna will receive an upfront payment of $330…
We haven't written up this one. Benzinga has the full story — the link below goes straight to it.